A Study for Patients With Secondary Progressive Multiple Sclerosis (MAESTRO-01)

This study has been completed.
BioMS Technology Corp.
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
First received: March 24, 2009
Last updated: May 27, 2010
Last verified: May 2010

The purpose of this study is to determine whether MBP8298 is effective and safe in the treatment secondary progressive multiple sclerosis.

Dirucotide is generic name for MBP8298.

Condition Intervention Phase
Secondary Progressive Multiple Sclerosis
Drug: dirucotide
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo Controlled Multicentre Study To Evaluate The Efficacy And Safety Of MBP8298 In Subjects With Secondary Progressive Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Increase in the time to worsening of disability by Kurtzke Expended Disability Status (EDSS). [ Time Frame: baseline, 3mos, 6mos, 9mos, 12mos, 15mos,18mos, 21mos, 24mos ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • degree of change in EDSS [ Time Frame: baseline, 24mos ] [ Designated as safety issue: No ]
  • Brain Atrophy by MRI [ Time Frame: baseline, 12mos, 24mos ] [ Designated as safety issue: No ]
  • Activity analysis of T2 and Gadolinium enhancing lesions [ Time Frame: 12mos and 24mos ] [ Designated as safety issue: No ]
  • Lesion burden [ Time Frame: 12mos and 24mos ] [ Designated as safety issue: No ]
  • Degree of change in MS Functional Composite Index (MSFC) [ Time Frame: baseline, 3mos, 6mos, 9mos, 12mos, 15mos, 18mos, 21mos, 24mos ] [ Designated as safety issue: No ]
  • Relapse rates [ Time Frame: baseline, 3mos, 6mos, 9mos, 12mos, 15mos,18mos, 21mos, 24mos ] [ Designated as safety issue: No ]
  • Quality of life as measured by Short Form 36 (SF-36) or MSQoL54 [ Time Frame: baseline, 6mos, 12mos, 18mos, 24mos ] [ Designated as safety issue: No ]

Enrollment: 596
Study Start Date: December 2004
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dirucotide Drug: dirucotide
500mg, intravenous, dosed once every six months for 18 months
Other Names:
  • MBP8298
  • LY2820671
Placebo Comparator: Placebo Drug: Placebo
intravenous, once every six months for 18 months


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Documented history of SPMS
  • Absence of relapse in the 3mos prior to baseline
  • EDSS of 3.5 - 6.5
  • Pyramidal or Cerebellar FSS greater than or equal to 3
  • A cohort of 100 HLA DR2/4 negative patients is required. Once enrollment to this cohort is complete, all further patients are required to be HLA DR2/4 positive.
  • Informed consent
  • Subject reliability and compliance

Exclusion Criteria:

  • Diagnosis of Primary Progressive MS
  • Subjects have previously received MBP8298
  • Recent history of malignancy, with the exclusion on basal cell carcinoma.
  • Steroid therapy within 30 days prior to first study specific procedure or any other treatment known to be used for putative or experimental MS treatment
  • Therapy with beta-interferon, glatiramer acetate within 3 mos or mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating or immunosuppressive drugs including recombinant or non-recombinant cytokines or plasma exchange within 6 mos prior to performance of the first study-specific test, with the exception of corticosteroids or ACTH for relapse treatment.
  • Initiation or discontinuation of therapy with 4-AP or 3,4-DAP at any time during the study period.
  • History of anaphylactic/anaphlactoid reactions to glatiramer acetate
  • Abnormal lab values at the Screening Visit deemed by the Investigator to be clinically significant
  • Known allergy to Gadolinium-DTPA
  • Treatment at any time with Cladribine, total lymphoid irradiation, monoclonal antibody treatment
  • Treatment at any time wtih an altered peptide ligand
  • Any conditions that could interfere with the performance of study specific procedures e.g.MRI
  • Previous randomization to this study
  • Known positivity for HIV, Hepatitis B, or Hepatitis C
  • Participation in any other non-MS clinical trial within 30 days prior to performance of the first study specific test or any investigational therapy in the past 6 mos.
  • Females who are breast feeding, pregnant or not using a medically approved method of contraception regularly
  • Known or suspected current or past alcohol or drug abuse (within the last year)
  • Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements
  • Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00869726

Canada, Ontario
St. Michaels Hospital
Toronto, Ontario, Canada, M5B 1W8
Copenhagen University Hospital
Kobenhavn, Denmark, 2100
West Tallinn Central Hospital
Tallinn, Estonia, 10617
Terveystalo Turku Kuvantaminen
Turku, Finland, 20101
Heinrich Heine Universitaets
Duesseldorf, Germany, 40225
Vecmilgravis Hospital
Riga, Latvia, 1015
Sittard, Netherlands, 6131 BK
Hospital Duran I Reynals
Barcelona, Spain, 08907
Karolinska Universitetssjukhus
Stockholm, Sweden, 14186
United Kingdom
Walton Hospital
Liverpool, United Kingdom, L97LJ
Sponsors and Collaborators
Eli Lilly and Company
BioMS Technology Corp.
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 317-615-4559 Mon-Fri 9am-5pm Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Responsible Party: Chief Medical Officer, Eli Lilly
ClinicalTrials.gov Identifier: NCT00869726     History of Changes
Other Study ID Numbers: 12788  I3E-BM-MSAB  MBP8298-01 
Study First Received: March 24, 2009
Last Updated: May 27, 2010
Health Authority: Canada: Health Canada
United States: Food and Drug Administration
Denmark: Danish Medicines Agency
Estonia: The State Agency of Medicine
Finland: Finnish Medicines Agency
Germany: Federal Institute for Drugs and Medical Devices
Latvia: State Agency of Medicines
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Spain: Spanish Agency of Medicines
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis
Neoplasm Metastasis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Neoplastic Processes
Nervous System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 26, 2016